Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | AKT2 | P31751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12669495 | 0.88 | CCR1 (0.36) | CCR1ADRB1KCNH2AKT1AKT2 | |
| Hydrochloric Acid SCHEMBL13387889 | 0.86 | CCR1 (0.36) | CCR1ADRB1KCNH2AKT1AKT2 | |
| SCHEMBL13386499 | 0.82 | AKT1 (0.40) | CCR1ADRB1KCNH2AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL13386459 | 0.79 | KDM1A (0.34) | HRH4HRH3L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL1873566 | 0.75 | LOXL2 (0.45) | CCR1KCNH2SCN10AHRH4HRH3 | |
| SCHEMBL1672692 | 0.74 | LMNA (0.40) | CCR1ADRB1KCNH2SCN10A | |
| Trifluoroacetic Acid SCHEMBL13386449 | 0.74 | AKT1 (0.36) | HRH4HRH3L3MBTL1AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1670540 | 0.73 | SCN10A (0.46) | SCN10AHRH4HRH3 | |
| SCHEMBL1670536 | 0.73 | CCR1 (0.43) | CCR1ADRB1KCNH2SCN10A | |
| SCHEMBL12002508 | 0.72 | LMNA (0.45) | CCR1ADRB1KCNH2SCN10AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056858-B2 | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| EP-2491028-B1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-12-11 | — | — | EP | disclosed |
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| CN-102666526-A | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists | BOEHRINGER INGELHEIM INT | 2012-09-12 | — | — | CN | disclosed |
| EP-2491028-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270870-A1 | Indazole and Pyrazolopyridine Compounds As CCR1 Receptor Antagonists | CCR1, CCRL2, CCR3 | CCR1 1/4885ADRB1 31/4885KCNH2 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.